The team of chemical engineers will be honored for their “enabling technology” at the organization’s 37th Edison Patent Awards Ceremony on November 3. They are among 12 winners this year.
Their patent, “Solventless Mixing Process for Coating Pharmaceutical Ingredients” (U.S. 9,107,851), is for a process that combines water insoluble and soluble polymers to form a highly structured particle coating layer, spread as a composite film in a single, high intensity, vibratory process so that the bitter taste of the drug is masked, while not impeding its delivery.
The process allows them to coat fine particles less than the diameter of a human hair in width without using water, organic solvents or heat. The technology has been licensed by a global health care company that develops both drugs and their delivery systems. The coating in that instance is a fine layer of wax that will be used to mask bitter tastes.
Capece is a senior scientist at Chicago-based AbbVie, Inc., a biopharmaceutical company, and To is a senior product development scientist at Colorcon, Inc., a global pharmaceutical product development company. Both worked with Davé at the New Jersey Center for Engineered Particulates while they were Ph.D. students at NJIT.
“This year’s individual and patent award winners showcase the breadth and depth of STEM leadership and innovation in New Jersey,” said R&D Council President Anthony Cicatiello in a release this week. “New Jersey is STEM strong. Dating back to the beginning with Edison, then Bell Labs and our state’s robust pharmaceutical industry, jumping to present day inventions and discoveries like those we are honoring in this year’s Edison Awards class, New Jersey continues to be an innovation powerhouse.”
The Council’s awards this year will go to innovative patent work spanning 11 categories, including agriculture, biotechnology, defense, drug delivery technology, enabling technology, energy, industrial process, industrial product, medical device, medical technology and telecommunications.
Among the other recipients are AdvanSix (Honeywell), ExxonMobil, Immunomedics, Lockheed Martin, Merck, NJIT, Nokia Bell Labs, Princeton Plasma Physics Laboratory, Rutgers University Siemens and TE Connectivity.